According to the official website of "Maker China", on November 18, 2024,
the Network Security Industry Development Center of the Ministry of Industry and
Information Technology (the Information Center of the Ministry of Industry and
Information Technology) officially announced that the "complete biomedical
industry chain of animal organs and secretions" project of our group has
successfully ranked among the top 500 enterprises of the national enterprise
group in the 9th "Maker China" SME Innovation and Entrepreneurship
Competition.
The "Complete biomedical industry chain of animal organs and secretions"
project of our group was selected as the top 500 national enterprise Group of
the 9th "Maker China" Small and Medium-sized Enterprise Innovation and
Entrepreneurship Competition
In recent years, Qingdao Jiulong Biomedical Group has always been
implementing the strategic policy of science and technology and talent to
develop enterprises, and has explored a characteristic development path with
innovation as the core. In terms of international certification of
pharmaceutical products, the Group has set four milestones: first, in August
2008, the heparin sodium API was approved by the US Food and Drug Administration
(FDA), and subsequently two workshops and laboratories were re-certified by FDA
with zero defects; Secondly, in January 2013, HCG drug substance was also
successfully approved by the US FDA, and it has successfully passed two
re-certifications in April 2016 and August 2024. Third, in November 2019,
heparin sodium passed the on-site inspection certification of PMDA in Japan;
Finally, in July 2024, the HCG API was also certified for field inspection by
the Japanese PMDA. So far, a total of three workshops of the Group have obtained
dual certification from the US FDA and Japan PMDA, which is unique in the
domestic pharmaceutical industry.
The Group has also won a number of honorary titles, including "High-tech
Enterprise", "Torch Plan", "Qingdao's first batch of biotechnology Backbone
Enterprises", "Qingdao's Top 100 Science and Technology Private Enterprises",
"Domestic Manufacturing Invisible Champion", and Qingdao's "Specialized and
Special New" Demonstration Enterprise. In addition, the State Intellectual
Property Office has accepted 345 invention patent applications submitted by the
group, of which 50 have been authorized.
These achievements not only highlight Qingdao Jiulong Biomedical Group's
outstanding position in the field of biomedicine, but also reflect the group's
relentless pursuit of innovation and quality.